Stock Track | Alvotech Plunges 5.04% After Hours on Q1 Earnings Miss and Revenue Decline

Stock Track05-07

Alvotech's stock fell 5.04% in post-market trading on Wednesday, following the release of its first-quarter financial results.

The biotechnology company reported revenue of $105.9 million for Q1 2026, a 20.3% decrease from the same period last year and significantly below analyst estimates of $140.85 million. Earnings per share were breakeven, missing expectations of 2 cents per share.

CEO Lisa Graver stated that both revenues and EBITDA were impacted by a production slowdown related to facility improvements, with a recovery expected as normal operations resume. The company maintained its full-year revenue guidance of $650-$700 million and adjusted EBITDA guidance of $180-$220 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment